About
Why CanLiv?
Cancers of the bile ducts, gallbladder and liver – known as
hepatobiliary cancers affect several hundred thousand people around the world every year. Primary liver cancer,
hepatocellular carcinoma (HCC) is the 4th leading cause of cancer death worldwide. Cancers of the bile ducts (cholangiocarcinoma) and gallbladder are relatively uncommon, but in some countries such as Japan, Chile, and Thailand, they are leading causes of cancer. The incidence of both HCC and cholangiocarcinoma is increasing significantly in the United States. Learn about the rising rates of liver cancer by reading
"Liver and thyroid cancer rates rise".
Because hepatobiliary cancers are relatively uncommon in developed countries, have few effective treatment options and very little research funding, they are often referred to as “orphan” tumors.
What We Do:
CanLiv - The Hepatobiliary Cancers Foundation was created by a group of physicians, scientists and other individuals who are dedicated to improving the treatment options and survival for hepatobiliary cancer patients by:
- Providing accurate, current Patient Resources to assist patients and their families in understanding their cancer diagnosis and finding the best possible treatment options.
- Enaging and uniting the cancer research and patient communities to drive the science that will improve hepatobiliary cancer patients' outcome.
- Sponsoring an annual Biliary Cancer Translational Research Symposium. Read about the 2010 Symposium in the Gallery.
Last Updated on 2/10/2012 11:31:40 AM